Back to today’s briefing

Story perspectives

FDA Approves GSK's Nucala for Uncontrolled COPD Treatment

5/23/2025

38 8

Summary

Story summary

The FDA has granted approval for GSK's Nucala (mepolizumab) as an additional treatment for adults struggling with uncontrolled COPD and an eosinophilic phenotype. Backed by the MATINEE and METREX trials, Nucala demonstrated a 21% reduction in moderate to severe exacerbations compared to a placebo, marking a significant milestone in COPD care with its fifth indication in the U.S.

1 of 1

Story summary

The FDA has granted approval for GSK's Nucala (mepolizumab) as an additional treatment for adults struggling with uncontrolled COPD and an eosinophilic phenotype. Backed by the MATINEE and METREX trials, Nucala demonstrated a 21% reduction in moderate to severe exacerbations compared to a placebo, marking a significant milestone in COPD care with its fifth indication in the U.S.